TABLE 2

Prognostic performances of laboratory biomarkers and risk assessment models with regard to an adverse 30-day outcome

	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	LR+ (95% CI)	LR− (95% CI)
Laboratory biomarker
hsTnT ≥14 pg·mL⁻¹	1.00 (0.80–1.00)	0.40 (0.34–0.46)	0.09 (0.06–0.14)	1.00 (0.96–1.00)	1.67 (1.50–1.84)
NT-proBNP ≥600 pg·mL⁻¹	1.00 (0.80–1.00)	0.51 (0.45–0.57)	0.11 (0.07–0.17)	1.00 (0.97–1.00)	1.96 (1.80–2.32)
Copeptin ≥24 pmol·L⁻¹	0.73 (0.48–0.89)	0.66 (0.60–0.72)	0.11 (0.07–0.19)	0.98 (0.94–0.99)	2.18 (1.54–3.10)	0.40 (0.17–0.93)
Copeptin ≥24 pmol·L⁻¹ and hsTnT ≥14 pg·mL⁻¹ and NT-proBNP ≥600 pg·mL⁻¹	0.73 (0.48–0.89)	0.83 (0.77–0.87)	0.20 (0.12–0.32)	0.98 (0.95–0.99)	4.25 (2.80–6.30)	0.32 (0.14–0.75)
Risk assessment models
ESC 2014 algorithm (intermediate–high risk versus low risk/intermediate–low risk)	0.67 (0.42–0.85)	0.70 (0.64–0.75)	0.12 (0.06–0.20)	0.97 (0.94–0.99)	2.22 (1.48–3.32)	0.48 (0.23–0.98)
Bova score (intermediate–high risk versus low risk/intermediate–low risk)	0.33 (0.15–0.58)	0.85 (0.80–0.88)	0.11 (0.05–0.24)	0.96 (0.92–0.98)	2.15 (1.00–4,66)	0.79 (0.55–1.13)

Sensitivity, specificity, positive and negative predictive values and positive and negative likelihood ratios of dichotomised/dichotomous biomarkers, risk assessment models and combination of biomarkers with regard to an adverse 30-day outcome. PPV: positive predictive value; NPV: negative predictive value; LR+/−: positive/negative likelihood ratio; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-brain natriuretic peptide; ESC: European Society of Cardiology.